Screener
Mirum Pharmaceuticals, Inc. MIRM Accrued clinical trials
Accrued clinical trials at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:AccruedClinicalTrialsCurrent.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued sales deductions and other | $62,501 | $51,375 |
| Accrued compensation and related benefits | 28,389 | 47,276 |
| Accrued clinical trials | 22,872 | 13,959 |
| Accrued professional service fees | 21,886 | 17,292 |
| Accrued contract manufacturing and non-clinical costs | 17,670 | 8,721 |
| Accrued royalties payable | 16,204 | 16,208 |
| Operating lease liabilities, current | 2,405 | 2,139 |
| Accrued loss on firm purchase commitments | 2,107 | 2,107 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s accrued clinical trials?
- Mirum Pharmaceuticals, Inc. (MIRM) reported accrued clinical trials of $22.87M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s accrued clinical trials changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s accrued clinical trials increased by 100.3% year-over-year, from $11.42M to $22.87M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s accrued clinical trials?
- Over 2 years (2023 to 2025), Mirum Pharmaceuticals, Inc.'s accrued clinical trials has grown at a 38.6% compound annual growth rate (CAGR), from $7.27M to $13.96M.
- What does accrued clinical trials mean?
- Accrued clinical trials as reported by Mirum Pharmaceuticals, Inc. Common Stock.
Ask your AI about Mirum Pharmaceuticals, Inc.'s accrued clinical trials.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude